Page last updated: 2024-10-27

foscarnet and Seizures

foscarnet has been researched along with Seizures in 6 studies

Foscarnet: An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpesviruses and HIV.
phosphonoformic acid : Phosphoric acid in which one of the hydroxy groups is replaced by a carboxylic acid group. It is used as the trisodium salt as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.

Seizures: Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.

Research Excerpts

ExcerptRelevanceReference
"Neutropenia was more common in patients assigned to ganciclovir than to foscarnet (34% vs 14%; P = ."9.08Morbidity and toxic effects associated with ganciclovir or foscarnet therapy in a randomized cytomegalovirus retinitis trial. Studies of ocular complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group. ( , 1995)
"Neutropenia was more common in patients assigned to ganciclovir than to foscarnet (34% vs 14%; P = ."5.08Morbidity and toxic effects associated with ganciclovir or foscarnet therapy in a randomized cytomegalovirus retinitis trial. Studies of ocular complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group. ( , 1995)
"Foscarnet was discontinued due to progressive renal insufficiency in all three patients (days 11, 19, and 21)."5.07A dose escalation study to determine the toxicity and maximally tolerated dose of foscarnet. ( Koenig, S; Polis, MA; Seidel, EA, 1993)
"We report two cases of seizures and one case of hand cramping and finger paresthesia after starting foscarnet therapy with no evidence of predisposing risk factors, such as serum laboratory abnormalities, renal dysfunction, or known central nervous system (CNS) involvement."3.69Neurologic sequelae associated with foscarnet therapy. ( Liu, YQ; Lor, E, 1994)
"Penile ulcers are best managed by stopping the infusion until the ulcers heal; they may be prevented by paying careful attention to personal hygiene."2.40Minimising the dosage-limiting toxicities of foscarnet induction therapy. ( Jayaweera, DT, 1997)
"We present a patient with polymorphic ventricular tachycardia and subsequent ventricular fibrillation with acquired long QT syndrome secondary to herpes encephalitis."1.38Polymorphic ventricular tachycardia in a patient with herpes encephalitis. ( Blaschke, D; Boldt, LH; Haverkamp, W; Huemer, M; Parwani, A; Rolf, S; Wutzler, A, 2012)
"The potential for convulsions induced by the coadministration of ciprofloxacin (CPFX) and foscarnet (PFA) may be due not to a change in the distribution of CPFX to the brain but to a potential CPFX-induced inhibition of gamma-aminobutyric acid (GABA)-GABA(A) receptor binding in the presence of PFA."1.30Neurotoxicodynamics of the interaction between ciprofloxacin and foscarnet in mice. ( Iga, T; Kawakami, JI; Matsuo, H; Nagata, A; Ryu, M; Sawada, Y; Uchida, T; Yamamoto, K, 1998)

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's5 (83.33)18.2507
2000's0 (0.00)29.6817
2010's1 (16.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Huemer, M1
Boldt, LH1
Wutzler, A1
Parwani, A1
Rolf, S1
Blaschke, D1
Haverkamp, W1
Lor, E1
Liu, YQ1
Seidel, EA1
Koenig, S1
Polis, MA1
Jayaweera, DT1
Matsuo, H1
Ryu, M1
Nagata, A1
Uchida, T1
Kawakami, JI1
Yamamoto, K1
Iga, T1
Sawada, Y1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Foscarnet-Ganciclovir CMV Retinitis Trial[NCT00000136]Phase 3234 participants (Actual)Interventional1990-03-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Mortality

(NCT00000136)
Timeframe: All patients enrolled will be followed until a common study closing date, which was chosen to provide a minimum of 1 year of follow-up for all patients enrolled in the trial.

Interventionparticipants (Number)
Foscarnet107
Ganciclovir127

Reviews

1 review available for foscarnet and Seizures

ArticleYear
Minimising the dosage-limiting toxicities of foscarnet induction therapy.
    Drug safety, 1997, Volume: 16, Issue:4

    Topics: Animals; Antiviral Agents; Cytomegalovirus Infections; Dose-Response Relationship, Drug; Female; Fos

1997

Trials

2 trials available for foscarnet and Seizures

ArticleYear
Morbidity and toxic effects associated with ganciclovir or foscarnet therapy in a randomized cytomegalovirus retinitis trial. Studies of ocular complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group.
    Archives of internal medicine, 1995, Jan-09, Volume: 155, Issue:1

    Topics: Acute Kidney Injury; Adolescent; Adult; AIDS-Related Opportunistic Infections; Cytomegalovirus Retin

1995
A dose escalation study to determine the toxicity and maximally tolerated dose of foscarnet.
    AIDS (London, England), 1993, Volume: 7, Issue:7

    Topics: Acquired Immunodeficiency Syndrome; Adult; Creatinine; Dose-Response Relationship, Drug; Foscarnet;

1993

Other Studies

3 other studies available for foscarnet and Seizures

ArticleYear
Polymorphic ventricular tachycardia in a patient with herpes encephalitis.
    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2012, Volume: 19, Issue:3

    Topics: Acute Disease; Acyclovir; Antiviral Agents; Defibrillators, Implantable; Electrocardiography; Enceph

2012
Neurologic sequelae associated with foscarnet therapy.
    The Annals of pharmacotherapy, 1994, Volume: 28, Issue:9

    Topics: Acquired Immunodeficiency Syndrome; Adult; Foscarnet; Hand; Humans; Infusions, Intravenous; Male; Mu

1994
Neurotoxicodynamics of the interaction between ciprofloxacin and foscarnet in mice.
    Antimicrobial agents and chemotherapy, 1998, Volume: 42, Issue:3

    Topics: Animals; Anti-Infective Agents; Antiviral Agents; Brain; Ciprofloxacin; Drug Interactions; Foscarnet

1998